Compare Stocks → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLSNNASDAQ:MISTNASDAQ:MNPRNASDAQ:ONCYNASDAQ:OTIC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsMISTMilestone Pharmaceuticals$1.70+4.3%$1.66$1.33▼$4.49$90.36M1.77311,834 shs90,452 shsMNPRMonopar Therapeutics$0.65+2.8%$0.74$0.27▼$1.75$11.34M1.194.39 million shs85,559 shsONCYOncolytics Biotech$1.06+1.9%$1.07$0.88▼$3.39$79.95M1.93373,844 shs55,895 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/A10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%MISTMilestone Pharmaceuticals-0.61%-7.12%-6.32%+5.84%-59.45%MNPRMonopar Therapeutics-1.27%-16.84%-8.35%+72.07%-48.62%ONCYOncolytics Biotech-1.89%-1.89%+4.00%-15.45%-11.11%OTICOtonomy0.00%0.00%0.00%0.00%0.00%Putin and other countries have a plan (Ad)Did you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AMISTMilestone Pharmaceuticals2.3051 of 5 stars3.43.00.00.03.22.50.0MNPRMonopar Therapeutics2.8905 of 5 stars3.55.00.00.02.11.70.6ONCYOncolytics Biotech0.8194 of 5 stars3.53.00.00.00.60.00.0OTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunonN/AN/AN/AN/AMISTMilestone Pharmaceuticals2.75Moderate Buy$10.75532.35% UpsideMNPRMonopar Therapeutics3.00Buy$2.00207.69% UpsideONCYOncolytics Biotech3.00Buy$4.00277.36% UpsideOTICOtonomyN/AN/AN/AN/ACurrent Analyst RatingsLatest MIST, MNPR, OTIC, CLSN, and ONCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024MNPRMonopar TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$2.004/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.003/22/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.003/5/2024MISTMilestone PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$6.00 ➝ $5.002/26/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00MISTMilestone Pharmaceuticals$1M90.36N/AN/A$0.50 per share3.40MNPRMonopar TherapeuticsN/AN/AN/AN/A$0.38 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AMISTMilestone Pharmaceuticals-$59.69M-$1.39N/AN/AN/AN/A-170.99%-64.45%5/9/2024 (Estimated)MNPRMonopar Therapeutics-$8.40M-$0.61N/AN/AN/AN/A-115.79%-88.05%5/9/2024 (Estimated)ONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ALatest MIST, MNPR, OTIC, CLSN, and ONCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023MNPRMonopar Therapeutics-$0.17-$0.12+$0.05-$0.12N/AN/A3/21/2024Q4 2023MISTMilestone Pharmaceuticals-$0.30-$0.32-$0.02-$0.32N/AN/A3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52MISTMilestone Pharmaceuticals2.9710.1110.11MNPRMonopar TherapeuticsN/A4.174.17ONCYOncolytics BiotechN/A9.019.01OTICOtonomyN/A1.741.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%MISTMilestone Pharmaceuticals86.18%MNPRMonopar Therapeutics1.83%ONCYOncolytics Biotech6.82%OTICOtonomy41.23%Insider OwnershipCompanyInsider OwnershipCLSNImunon4.66%MISTMilestone Pharmaceuticals10.40%MNPRMonopar Therapeutics41.60%ONCYOncolytics Biotech0.10%OTICOtonomy1.09%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableMISTMilestone Pharmaceuticals4753.15 million47.62 millionOptionableMNPRMonopar Therapeutics1117.45 million10.19 millionNot OptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableOTICOtonomy5168.53 million67.78 millionOptionableMIST, MNPR, OTIC, CLSN, and ONCY HeadlinesSourceHeadlineTop 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023straight.com - April 21 at 9:08 PMAllergic Contact Dermatitis and Topical Antibioticsmedscape.com - September 10 at 4:13 PMHearing Loss in Adultsnejm.org - August 21 at 11:30 PMResearch Publicationsslu.edu - August 4 at 7:44 PMManagement of Pediatric Otitis Mediamedscape.com - May 11 at 11:26 PMHearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPRnews.google.com - May 8 at 10:11 AMAlluvial Capital Management Q1 2023 Letter To Partners - Seeking Alphanews.google.com - April 28 at 7:44 AMVertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital Journalnews.google.com - April 27 at 9:58 AMHearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPRnews.google.com - April 25 at 4:57 PMENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital Journalnews.google.com - April 24 at 7:52 AMHearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital Journalnews.google.com - April 11 at 10:37 PMENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital Journalnews.google.com - April 10 at 7:51 AM[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital Journalnews.google.com - April 10 at 7:51 AMHearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital Journalnews.google.com - April 3 at 7:09 PMHearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints Newsnews.google.com - March 30 at 1:22 PMAlector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMMathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMBoehringer reports robust sales led by type 2 diabetes and ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMSeelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMSpiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to ... - PR Newswirenews.google.com - March 29 at 8:47 PMSpiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear ... - BioSpacenews.google.com - March 29 at 10:46 AMOtic Drug Market Size Historical Growth, Analysis, Opportunities and Forecast To 2029| Pediapharm Novus Therap - openPRnews.google.com - March 27 at 9:52 AMHearing Loss Pipeline Drugs and Companies Insight Report, 2023 ... - Digital Journalnews.google.com - March 23 at 9:50 AMHearing Loss Disease Treatment Market 2023 key developmental ... - openPRnews.google.com - March 22 at 6:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesCanoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetApril 2, 2024 9:15 AMView Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetUiPath Cuts Q1 and Raises Full Year GuidanceMarch 26, 2024 7:41 AMView UiPath Cuts Q1 and Raises Full Year GuidanceASML Fires Warning Shot For Tech InvestorsApril 17, 2024 9:05 AMView ASML Fires Warning Shot For Tech Investors3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AICan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Milestone PharmaceuticalsNASDAQ:MISTMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Monopar TherapeuticsNASDAQ:MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.OtonomyNASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.